![]() |
Home
Search
Study Topics
Glossary
|
Study 19 of 4246 for search of: | United States, Washington |
![]() |
Previous Study | Return to Search Results | Next Study |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Merck Bristol-Myers Squibb |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00130806 |
This is a study to evaluate the effectiveness and tolerability of an investigational drug in patients with type 2 diabetes (a specific type of diabetes) who are not currently treated with insulin.
Condition | Intervention | Phase |
---|---|---|
Type 2 Diabetes Mellitus |
Drug: MK0478 (muraglitazar) Drug: Comparator: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Study to Assess the Efficacy and Tolerability of MK-0478 (Muraglitazar, Also, BMS 298585) Coadministered With Insulin in Patients With Type 2 Diabetes |
Estimated Enrollment: | 600 |
Study Start Date: | October 2005 |
The duration of treatment is 30 weeks.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Medical Monitor | Merck |
Study ID Numbers: | 2005_020 |
Study First Received: | August 12, 2005 |
Last Updated: | May 17, 2006 |
ClinicalTrials.gov Identifier: | NCT00130806 |
Health Authority: | United States: Food and Drug Administration |
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Insulin |